The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5
mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular
hallmarks of aging in humans. Participants who are 55-80 years old and insulin resistant or
prediabetic will be randomized to treatment and can expect to be on study for up to
approximately 38 weeks. Participants aged 18-35 will not receive the intervention and can
expect to be on study for up to approximately 8 weeks.